Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

L6292

Sigma-Aldrich

Lisinopril

≥98% (HPLC)

Sinônimo(s):

(S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C21H31O5N3 · 2H2O
Número CAS:
83915-83-7
Peso molecular:
441.52
Número MDL:
MFCD01698825
Código UNSPSC:
12352200
ID de substância PubChem:
329817636
NACRES:
NA.32

Ensaio

≥98% (HPLC)

forma

solid

cor

white

solubilidade

H2O: ≥10 mg/mL
DMSO: ~6.5 mg/mL (with heating and sonicating)

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

chave InChI

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Informações sobre genes

human ... ACE(1636)

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

Lisinopril has been used to study the antifibrotic effect in duchenne muscular dystrophy mice. It has been used to study the changes in renal-structure and -function in TGR(mRen2)27 (transgenic rat harboring the murine Ren-2 gene) rats upon long term darbepoetin α treatment.

Ações bioquímicas/fisiológicas

Angiotensin converting enzyme (ACE) inhibitor.

Características e benefícios

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Health hazard
GHS08

Palavra indicadora

Danger

Frases de perigo

H360D,H373

Classificações de perigo

Repr. 1A - STOT RE 2

Órgãos-alvo

Kidney

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, type N95 (US)

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 7

1 of 7

Benazepril hydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

B0935

Benazepril hydrochloride

Enalapril maleate salt powder, ≥98% (TLC)

Sigma-Aldrich

E6888

Enalapril maleate salt

Enalaprilat dihydrate ≥98% (HPLC)

Sigma-Aldrich

E9658

Enalaprilat dihydrate

Valsartan ≥98% (HPLC)

Sigma-Aldrich

SML0142

Valsartan

Captopril Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1307

Captopril

Carvedilol ≥98% (HPLC), solid

Sigma-Aldrich

C3993

Carvedilol

Losartan potassium

Supelco

61188

Losartan potassium

Anne-Roos S Frenay et al.
Journal of the renin-angiotensin-aldosterone system : JRAAS, 13(2), 232-238 (2012-01-28)
Erytropoietin (EPO) has cytoprotective and angiogenic properties and has a beneficial effect in ischaemic conditions. Since the development of renal interstitial abnormalities are often associated with ischaemia, we studied the effects of the long-acting EPO analogue darbepoetin alpha (DA) on
Jason V Baker et al.
PloS one, 7(10), e46894-e46894 (2012-10-20)
Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed. We conducted a 2 × 2 factorial feasibility study of lisinopril (L) (10 mg daily) vs L-placebo in combination
Jill A Rafael-Fortney et al.
Circulation, 124(5), 582-588 (2011-07-20)
Nearly universal cardiomyopathy in Duchenne muscular dystrophy (DMD) contributes to heart failure and death. Because DMD patients show myocardial fibrosis well before functional impairment, we postulated that earlier treatment using drugs with antifibrotic effect may be beneficial. Three groups of
Tatjana Ignjatovic et al.
The Journal of biological chemistry, 277(19), 16847-16852 (2002-03-07)
Angiotensin I converting enzyme (kininase II; ACE) inhibitors are important therapeutic agents widely used for treatment in cardiovascular and renal diseases. They inhibit angiotensin II release and bradykinin inactivation; these actions do not explain completely the clinical benefits. We found
Nadir Ulu et al.
The Journal of pharmacology and experimental therapeutics, 345(3), 393-403 (2013-03-27)
Transactivation of epidermal growth factor receptor (EGFR) signaling by G protein-coupled receptors has been implicated in several cardiovascular (CV) conditions, including hypertension, heart failure, and cardiac and vascular hypertrophy. However, the therapeutic potential of EGFR inhibition in these conditions is
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica